Anti-angiogenic therapies in cancer clinical trials
- 1 October 1998
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 7 (10) , 1629-1655
- https://doi.org/10.1517/13543784.7.10.1629
Abstract
Strategies involving vasculature have widely been acknowledged to have therapeutic potential in the management of cancer and other diseases. Based on a large body of evidence from preclinical studies and early clinical trials there is considerable optimism that anti-angiogenesis and vascular targeting will be a major clinical therapy. This review considers some 30 anti-angiogenic and vascular targeting agents that are currently in cancer clinical trials and highlights specific problems relating to the assessment of the activity of these agents in patients, trial design, potential toxicities and resistance mechanisms.Keywords
This publication has 86 references indexed in Scilit:
- Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470New England Journal of Medicine, 1998
- Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin)Zeitschrift für Krebsforschung und Klinische Onkologie, 1996
- Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): Progress in supportive careSupportive Care in Cancer, 1996
- Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumoursEuropean Journal Of Cancer, 1995
- Therapeutic uses of heparin beyond its traditional role as an anticoagulantTrends in Pharmacological Sciences, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Administration of Pentosan Polysulfate to Patients With Human Immunodeficiency Virus-Associated Kaposi's SarcomaJNCI Journal of the National Cancer Institute, 1993
- Detectable Inhibition of Heparin-Binding Growth Factor Activity in Sera From Patients Treated With Pentosan PolysulfateJNCI Journal of the National Cancer Institute, 1993
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B?-hemolytic streptococcusZeitschrift für Krebsforschung und Klinische Onkologie, 1993